Somatostatin and somatostatin analogs
SRIFt was described originally by Krulich et al. [l] as a factor present in hypothalamic extracts capable of inhibiting GH release by cultured rat anteriorpituitarycells.Brazeauetal.
[2]characterized this factor as a cyclic peptide (SS14) consisting of 14 amino acids. Several years later, a second bioactive form, an NHz-terminally extended somatostatin molecule, consisting of 28 amino acids (SS28), was isolated and characterized [3] . In mammals, both SS14 and SS28 originate from a 10.3 kDa prohormone called preprosomatostatin [4] . Somatostatin has an inhibitory action on a variety of physiological functions in different organ systems, including the hypothalamus, the anterior pituitary gland, the gastrointestinal tract, and the endocrine and exocrine pancreas [5] . In the brain, somatostatin may have a role in neurotransmission, both stimulatory and inhibitory [6, 7] . On the basis of its widespread inhibitory actions, somatostatin may play a role in the treatment of human disease due to hyperfunction of the above organ systems. However, the clinical use of somatostatin was hampered because the native peptide had several disadvantages [S, 91. In particular, the need for continuous i.v. infusion due to its very short halflife in the circulation (< 3 min), its diversity of action (i.e. its potent inhibitory action on normal insulin secretion), and, finally, the rebound hypersecretion of hormones by normal tissues after 5514 infusion are major disadvantages [lo, 111. A logical step, therefore, was the development of structural analogs of somatostatin, not having the disadvantages of SS14 as described above. This research has led to the synthesis of a great number of somatostatin analogs; thus far, three of them, octreotide (SMS 201-995, Sandostatin), BIM-23014 (Lanreotide) and RC-160 (Octastatin, Vapreotide), are in clinical studies and/or use. Figure 1 shows the amino acid sequence of each of these analogs, in comparison with that of the native peptide. Until now, octreotide was the most widely used somatostatin analog for the treatment of human tumors [12] .
Bauer et al.
[ 131 originally developed via step-bystep modification of the conformationally stabilized central part of the SS14 molecule a series of highly potent octapeptide analogs, of which octreotide was the most active. This analog contains the sequence of residues 7-10 of SS14, Phe-Trp-Lys-Thr, essential for receptor binding, in which D-Trp was substituted for Trp ( Fig. 1 ). Octreotide can be given subcutaneously, has a half-life of approximately 2 hr and turned out to be 45 times more active than SS14 in inhibiting GH release in monkeys, 11 times more effective in inhibiting glucagon release, and most important, only 1.3 times more potent in inhibiting insulin release [13] . Thereafter, several analogs, related to octreotide, were synthesized and tested for their biological activity by Schally and co-workers [14, 15] . They found that substitution of Phe and Thr by Tyr and Val, respectively, at positions 3 and 6 resulted in a much higher potency for inhibition of GH secretion, but lower activity for inhibition of insulin and glucagon release in uiuo in rats. They also suggested that replacing Thr at position 8 with Trp may result in increased receptor affinity. This suggests that analogs containing the Tyr"/Va16 substitution may be more specific for GH inhibition, and that there may be selectivity in the actions of octapeptide analogs. Both RC-160 and BIM-23014 are Tyr3/Va16-containing somatostatin analogs; RC-160 also has Trp at position 8, and BIM-23014 PNal at position 1. In addition to RC-160, BIM-23104 was chosen with the intention of finding an analog with little effect on insulin and glucagon secretion but with a more profound effect on GH secretion [16, 17] . The above data also suggest the existence of multiple SS-R subtypes having selective affinities for structural analogs of somatostatin, and with a selective expression in different organ systems. 
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H-Whe-C;s-Tyr-0T~-Lys-Va+&-Trp-~, This concept was further substantiated by the recent cloning of at least five different human SSTR subtypes (see below). As has been mentioned above, along with octreotide, RC-160 and BIM-23014, many other somatostatin analogs have been synthesized thus far. In this review, we will summarize the relevant literature data on binding of somatostatin analogs to human SSTR subtypes, as well as SSTR subtype expression in normal and tumorous tissues, and we will discuss the clinical role of somatostatin analogs in relation to SSTR subtypes.
Somatostatin receptors in normal and tumorous tissues
Along with the widespread biological actions of somatostatin, high-affinitySS-Rs havebeenidentified in all somatostatin target tissues. High-affinity somatostatin binding sites have been demonstrated in the anterior pituitary gland, the endocrine and exocrine pancreas, the gastrointestinal tract and the central nervous system. It has also become evident that many human neuroendocrine tumors, often originating from somatostatin target tissues, carry receptors for somatostatin [18, 19] On the basis of their experiments, they suggested the existence of at least two somatostatin binding sites in the rat brain: an SS-R with high affinity for octreotide and an SS-R with low affinity for this somatostatin analog. Autoradiographic studies have also demonstrated the existence of SS-R subtypes in rat brain on the basis of distinct regional distribution patterns using different somatostatin analogs [24, 25] . Also, functional studies point to the presence of SS-R subtypes in the brain. Inhibition of forskolinstimulated adenylyl cyclase activity by somatostatin was observed in membrane preparations from the rat hippocampus and striatum but not from the substantia nigra. Moreover, octreotide solely inhibited adenylyl cyclase activity in the preparations, while SS14 also stimulated adenylyl cyclase activity at micromolar concentrations [26] , By using SS-R autoradiography, a differential binding pattern of SS14 or SS28 on the one hand and of octreotide on the other hand has also been observed in subgroups of human tumors. Potential sites for the attachment of N-linked carbohydrate side chains (-Asn-Xaa-Ser/Thr, Xaa being any amino acid except proline) are present in the deduced amino acid sequences of the cloned SSTRs. However, not all potential glycosylation sites are used. There are, for instance, attachment sites for sugar chains located in the signal peptide sequence and in a transmembrane spanning domain. It is unlikely that these sites will be glycosylated in vivo. Sugar chain addition could be of functional significance for the structure of the ligand binding site. Rens-Domiano and Reisine [32] found a reduced affinity for the iodinated somatostatin analog MK-678 after desialylation of brain SS-Rs and AtT20 cell SS-Rs. The role of each individual glycosylation site can be established in future studies via site-directed mutagenesis followed by expression of the mutant DNA construct.
Because the different molecular forms of the SS-R may represent different SSTR subtypes or processing variants of one SSTR subtype, the production of subtype-specific antibodies seems necessary to further understand and match the data derived from the molecular cloning and the crosslinking studies. Metabolic labeling in combination with immunoprecipitation studies will give a more precise insight into the biosynthesis and posttranslational modifications of SSTRs. A recent report mentions the production of a polyclonal antiserum raised against a synthetic peptide that codes for a specific part of the human SSTR2 sequence [33] .
Although the presence of different SS-R proteins has been studied extensively by the method of crosslinking in a variety of normal tissues [28] , much less is known with respect to different SS-R proteins in human tumors. In human breast tumors, the somatostatin analog BIM-23014 complexed with three distinct SS-R proteins of 27, 42 and 57 kDa, while there was a considerable heterogeneity among the tumor specimens in the expression of the different proteins [34, 35] . A significant positive correlation was found between the absence of sex steroid receptors and the simultaneous presence of the three BIM-23014 binding receptor proteins [34] .
Molecular biology. From the above data it is clear that in both normal tissues (i.e. brain) and tumorous tissues (i.e. human insulinomas) at least more than one SS-R subtype is present. This concept was confirmed recently by the cloning of five different human, mouse and rat SSTR subtypes (SSTRl-5). Because this review deals with the clinical use of somatostatin analogs in relation to SSTR subtypes, and differences have been reported in binding characteristics between the same human and rat SSTR subtypes, we will focus on the five human SSTR (hSSTR) subtypes only. The five hSSTR subtypes consisting of 391, 369, 418, 388 and 363 amino acids, respectively, show an amino acid identity ranging from 42 to 60% [36] . hSSTR1, hSSTR2, hSSTR3, hSSTR4 and hSSTR5 have been shown to be localized on chromosomes 14q13,17q24, 22q13.1, 20 and 16, respectively [37] [38] [39] [40] . In another study, Yasuda et al. reported localization of the hSSTR5 subtype to chromosome 20~11. 2 [41] . However, in this study an hSSTR5 genomic clone isolated from a human genomic library by hybridization with a polymerase chain reactiongenerated fragment of the rat SSTR4 gene [42] was used and may therefore be considered as an hSSTR4 clone. [49] have shown that activation of the human SSTRl-5 subtypes may also be linked to phospholipase C stimulation and Ca2+ mobilization. The order of potency for somatostatin-induced inositol phosphate production was hSSTR5 > hSSTR2 > hSSTR3 > hSSTR4 > hSSTR1 [50] . In addition, they found that inhibition of CAMP formation could be reversed by pertussis toxin, whereas SS-induced activation of phospholipase C and Ca2+ mobilization was blocked only partially by pertussis toxin in hSSTR2, hSSTR3 and hSSTR5 transfected COS-7 cells, indicating that both pertussis toxin-sensitive and -insensitive GTPbinding proteins may be linked to one hSSTR subtype. These investigators suggested that, similar to receptors for thyrotropin, luteinizing hormone, tachykinin and calcitonin, one human SSTR subtype may also be linked to more than one effector system [49, 50] . This is also evident from the observations of Buscail et al. [51] , who showed that both octreotide and RC-160 caused stimulation of tyrosine phosphatase activity in COS-7 cells transiently expressing hSSTR2, while RC-160 but not octreotide also stimulated phosphatase activity in cells transfected with the hSSTR1 subtype. In the same study, it was shown that in NIH 3T3 cells stably expressing hSSTR1 or 2, both RC-160 and octreotide inhibited bFGF-and bFGF-or FBS-stimulated cell proliferation, respectively, with RC-160 being slightly more efficacious than octreotide [51] .
Despite the fact that there is a relatively high homology in amino acid identity, a common link to adenylyl cyclase activity, a common G-protein coupling, and high-affinity binding of SS14 and SS28 to all hSSTR subtypes [47,48], several differences have been observed thus far in the binding affinities of structural analogs of somatostatin to the hSSTRl-5 subtypes. As has been mentioned before, all five hSSTR subtypes bind SS14 and SS28 with high affinity. Octreotide binds with high affinity to the hSSTR2 subtype and binds with moderate affinity to the hSSTR3 [44] and hSSTR5 subtypes ([36,38]; Table 1 ). However, this somatostatin analog shows no binding to the hSSTR1 [45, 52] and hSSTR4 [36, 53] subtypes. In several studies (although less extensively studied than octreotide), binding of RC-160 and BIM-23014 to human SSTR subtypes was investigated. RC-160 has a very low affinity, although higher than that of octreotide, for the hSSTR4 subtype [36, 53] , while it shows a higher affinity (approximately 2-to g-fold) in comparison with octreotide for the hSSTR5 subtype [36, 381. This higher affinity of RC-160 as compared with octreotide has also been demonstrated for the hSSTR1 and 2 subtypes (2-and 3-fold respectively; [51]). In the Raynor et al. [52] showed in extensive studies that BIM-23014 and octreotide possess a very low affinity for the hSSTR1 subtype and a relative high affinity (1.6 to 5.6 nM) for the mouse SSTR2 and 3 subtypes. Since octreotide binds to the human SSTR3 subtype with an approximately 6-fold lower affinity, this again emphasizes that care must be taken with the extrapolation of ligand-binding data of mouse and rat SSTR subtypes to the human situation. Interestingly, Raynor et al.
[52] also found that some linear analogs of somatostatin selectively bound to SSTR subtypes with subnanomolar affinities, whereas CGP 23966-like compounds (structure: cyclo[AhepLys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser]) bound to the hSSTR1 subtype, but not to the mouse SSTR2 subtype [45] . In addition, it was found that CGP-23966 bound with high affinity to the hSSTR3 subtype [44] . Therefore, studies directed to the development of somatostatin analogs, other than octapeptide analogs, may result in new classes of somatostatin analogs that might be of therapeutic value in the treatment of human tumors not expressing the hSSTR2 subtype, which has a high affinity for the somatostatin analogs octreotide, BIM-23014 and RC-160. Much of the therapeutic value of new agents will also depend on their pharmacokinetic properties, however. Depending on these properties, such analogs may be of therapeutic value in the treatment of those tumors that show no binding of octreotide, RC-160 and BIM-23014.
Taken together, these data indicate that there may be relative differences (up to lo-fold) in binding affinities to SSTRl-5 subtypes among the three octapeptide somatostatin analogs available for clinical use now. It is also clear that none of these analogs binds with high affinity to the hSSTR1, hSSTR3 and hSSTR4 subtypes, whereas all bind hSSTR2 and hSSTR5 with a high and relatively high affinity, respectively.
Somatostatin receptor subtype expression in human tumors
There is a limited number of studies, thus far, showing the expression of SSTR subtypes in human tumors. Greenman and Melmed [54] showed heterogeneous expression of the hSSTR1 and hSSTR2 subtypes in human pituitary tumors using RNAse protection assays. They found that hSSTR1 and hSSTR2 were expressed, respectively, in 3 of 7 and 9 of 10 GH-secreting pituitary adenomas, 4 of 5 and 0 of 5 prolactinomas, 1 of 9 and 5 of 9 nonfunctioning adenomas, and in 1 of 3 and 0 of 3 ACTH-secreting tumors. They also found that two acromegalic patients who responded to octreotide therapy exclusively expressed the hSSTR2 subtype in their tumors, suggesting that the hSSTR2 subtype mediates the antihormonal action of octreotide in these tumors. In this respect, the observation by Raynor et al. [52] that the potencies of various somatostatin agonists to inhibit growth hormone secretion in vitro were highly correlated with their potencies to inhibit radioligand binding to the mouse SSTR2 receptor, but not to the hSSTR1 or mouse SSTR3 subtype, is of particular interest. In the nonfunctioning pituitary adenomas, the role of the hSSTR2 subtype is less clear, although it has been shown recently that octreotide may also have an inhibitory action on gonadotrophin and/or gonadotrophin-subunit secretion by clinically nonfunctioning pituitary adenomas in vivo and in vitro [55, 56] . Panetta et al.* reported the presence of hSSTR2 and hSSTR3, but not hSSTR5 mRNA in a GH-adenoma, a prolactinoma, and one of two chromophobe adenomas. The other chromophobe adenoma did not express the hSSTR2,3 or 5 subtype. hSSTR1 and hSSTR4 expression was not tested.
The importance of the hSSTR2 subtype in mediating the clinical effects of octreotide is further substantiated by a recent study by Kubota et al. [57] . expression of hSSTR1, hSSTR2, hSSTR3 and hSSTR4 in two cases of glucagonoma and its metastatic lymph node in one case. In addition, a heterogeneous expression of these hSSTR subtypes was found in four insulinomas.
Whereas all insulinomas showed expression of hSSTR1 and hSSTR4, hSSTR2 was not detected in one case, and hSSTR3 was absent in two cases. One carcinoid expressed hSSTR1 and hSSTR4 only, while three pheochromocytomas expressed the hSSTR1 and hSSTR2 subtype only. None of the tumor samples showed expression of the hSSTR5 subtype. Most important, these investigators also showed that urinary S-hydroxyindole acetic acid (5HIAA) excretion in the patient with a metastatic carcinoid lacking hSSTR2 expression was not lowered by octreotide treatment, while octreotide treatment lowered plasma glucagon levels in the patient with an hSSTR2 positive glucagonoma.
This again strongly suggests that the efficacy of octreotide treatment may depend, at least in part, on the expression of hSSTR2 in tumors [57] . It should be noted, however, that amplification by RT-PCR of hSSTR subtype mRNAs from contaminating normal tissues cannot be excluded completely in these studies. Studies using in situ hybridization for the detection of hSSTR subtype mRNAs in tumor slices may help to answer this question. Of special importance in this respect is that Reubi et al. [ [70] . Freshly dispersed 7315b tumor cells do not express receptors for octreotide, while the number of SS-R rapidly increased during culturing of the cells in medium containing 10% FBS. At a low SS-R number, only antihormonal effects were observed, whereas at a higher SS-R number both antihormonal and antiproliferative effects of octreotide were found. Although there was a significant positive correlation between the inhibitory effect of octreotide on cell proliferation and the number of SS-R on 7315b tumor cells, the involvement of different SSTR subtypes could not be excluded [70] . Recently, we found that SS-R expression in 7315b tumor cells is highly estrogen dependent and that two major molecular forms of the SS-R (30 and 57 kDa), as determined by crosslinking of [1251-Ty8]octreotide to its receptor, were all stimulated by E2*. The presence of different molecular forms of the SS-R may represent different processing variants of the same SSTR or different SSTR subtypes (see section on cross-linking studies). In addition to this stimulatory effect of Ez on SS-R expression, which has also been observed in normal rat pituitary cells [73, 74] , glucocorticoids have a potent down-regulating effect on SS-R expression in , whereas in uiuo treatment of experimental tumor models with somatostatin analogs may also result in an increased number of somatostatin binding sites [79] . It would be of interest to know whether this up-regulation and/or down-regulation of SS-R is related to a particular SSTR subtype(s).
Finally, when studying the effects of somatostatin and somatostatin analogs on cell proliferation, other interesting observations have been made. In different cell systems such as rat mesangial cells [SO] , human hepatoma cells [69] and human pancreatic carcinoid cells [Sl] , both inhibitory and stimulatory effects by somatostatin (analogs) have been observed, depending on the culture conditions. In the absence of growth-stimulatory factors (i.e. FBS or insulin), stimulatory effects by somatostatin (analogs) are observed, whereas in FBS-or insulin-stimulated cultures predominantly inhibitory effects are seen. This strong dependency of the cell growth inhibitory effect by somatostatin (analogs) on the hormonal environment of the cells is also seen in human breast cancer cells [61] . In human meningioma tumor cell cultures, Koper et al. [82] also found a stimulatory effect of the somatostatin analog octreotide on cell proliferation.
Somatostatin inhibited forskolinstimulated CAMP formation in membrane preparations of the meningiomas, and it was hypothesized that stimulation by somatostatin (analogs) of the proliferation of human meningioma cells in vitro may be mediated via interference in the autocrine negative control of tumor cell growth due to inhibition of intracellular CAMP levels. In different human follicular and papillary carcinoma cell lines, variable effects have been reported of the effects of the somatostatin analogs octreotide and MK-678 on cell proliferation [83] . Whereas MK-678 inhibited cell proliferation in one follicular carcinoma cell line, octreotide induced a stimulatory effect on the same cell line. In a papillary carcinoma cell line, MK-678 significantly inhibited cell growth in a concentration-dependent manner, while the same cells showed a biphasic response to octreotide with an inhibition of cell proliferation at 0.2 to 10nM and no significant effect on cell proliferation at higher concentrations.
Finally, these investigators found that thyroid-stimulating hormone (TSH) and EGF altered the concentration-response relationship of MK-678 on the growth of another follicular carcinoma cell line. Taken together, it might be speculated that SSTR subtype expression is highly sensitive to regulatory effects of hormones, growth factors and/or steroid hormones, resulting in stimulatory effects as well as inhibitory effects by somatostatin (analogs) on the same cell type.
We recently compared the effects of octreotide, BIM-23014 and RC-160 on hormone release by cultured cells from human GH-secreting pituitary adenomas, from one gastrinoma, and from normal rat anterior pituitary cells [84] . We found that RC-160 was significantly more potent in its inhibitory effect on hormone release as compared with octreotide and BIM-23014 in all three cell systems. It is still unclear at present whether the difference between the hormone release inhibitory effects of these analogs is caused by interactions via different SSTR subtypes. However, our data may be in accordance with several reports of a higher affinity of RC-160 as compared with octreotide for certain hSSTR subtypes.
At present, it is also unclear which hSSTR subtype mediates the antiproliferative (or proliferative) effects of somatostatin analogs such as octreotide, BIM-23014 and RC-160. Since the hSSTR2 subtype, to which these analogs bind with high affinity, seems to be coupled to both inhibition of adenylyl cyclase activity and stimulation of phosphatase activity, this hSSTR subtype may be a candidate for mediating both effects. The hSSTR5 subtype, which is also coupled to adenylyl cyclase activity and which binds octreotide and RC-160 with a relative high affinity, may also be a candidate in CAMP-dependent inhibition of cell proliferation. However, the hSSTR5 subtype was not expressed in insulinomas, gastrinomas and carcinoids [57] . In the study by Greenman and Melmed [54] , no correlation was found between SSTR subtype expression and tumor size of human pituitary adenomas. However, the four non-functioning adenomas and the GHsecreting tumor that did not express hSSTR1 or 2 (see above) were particularly large and invasive. We recently found that the stable somatostatin analog Tyr3-octreotide was rapidly internalized in a high amount by AtT20 mouse pituitary tumor cells and in human GH-secreting pituitary adenoma cells*. In addition, we found that cultured cells from a human carcinoid also internalized this somatostatin analog to a high extent (2% of the dose of [lZsITyr3]octreotide added, after 4 hr of incubation; Table 2 ). Internalization of octreotide may well explain the rather long residence time of radioactivity on human tumors in viva in SS-R scintigraphy [12,95-971. A high rate of internalization is also of special importance when radiotherapy of certain SS-R-positive human cancers with (Y-or Pemitting * Hofland et al., Manuscript submitted for publication. isotopes coupled to somatostatin analogs is considered [12, 20, 98] . It would be of interest to know which hSSTR subtype(s) shows internalization in order to develop somatostatin analogs with high affinity for this particular subtype(s) that can be used for radiotherapy, and to investigate whether it is possible to (transiently) up-regulate the expression of this SSTR subtype(s) in order to improve the results of in viuo SS-R scintigraphy as well as the effects of radiotherapy using radiolabeled somatostatin analogs.
As has been discussed above, at least five different human SSTR subtypes have been cloned. All subtypes bind SS14 and SS28 with high affinity, whereas their affinity for numerous somatostatin analogs differs considerably. Octreotide binds with high affinity to the SSTR2 subtype, while this analog has a relatively high affinity to SSTR3 and SSTR.5 and shows no binding to SSTR subtypes 1 and 4. At present, it is unclear which SSTR subtype is involved in receptor-mediated endocytosis. Coupling to Gproteins seems to play a major role in agonistinduced receptor internalization [99] . Of interest in this respect is that the hSSTR2, hSSTR3 and hSSTR5 subtypes are linked to both pertussis toxin-sensitive and -insensitive GTP-binding proteins [49, 50] .
Future prospects
In conclusion, the recent cloning of at least five different somatostatin receptor subtypes has provided a major tool to study hSSTR subtype expression in human tumors. Furthermore, studies concerning the coupling of second messenger systems to hSSTR subtypes, as well as investigations linking hSSTR subtype expression to their function (i.e. antihormonal and antiproliferative effects), will give new insights into the functional role of hSSTR subtypes in human tumors. Finally, the development of new classes of somatostatin analogs with specificity to particular hSSTR subtypes may provide us with new drugs for the treatment of patients with tumors carrying SSTRs with low affinity for octapeptide analogs such as octreotide, BIM-23014 and RC-160. 
